Global Anticoagulants Market

Anticoagulants Comprehensive Study by Type (Vitamin K Antagonists, Non-VKA Oral Anticoagulants, Others), Application (Atrial Fibrillation & Heart Attack, Stroke, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Others), Route of Administration (Oral Anticoagulant, Injectable Anticoagulant), Drug Class (NOACs, Heparin & LMWH, Vitamin K Antagonist, Others) Players and Region - Global Market Outlook to 2030

Anticoagulants Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 7.3%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Anticoagulants
Anticoagulants are remedies that prevent coagulation of blood and preserve proper blood circulation. Due to increasing incidences of thrombotic disorders result in life-threatening diseases such as stroke, heart disorders and atrial fibrillation anticoagulants market is expected to grow utmost for the projected period and investment in research and development globally for healthcare infrastructure aimed at timely and effective diagnosis is key factor thriving the anticoagulants market

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR7.3%


Owing to increasing healthcare infrastructure in emerging economies instead of fragmented market anticoagulants market is expected to grow significantly for the forecasted period Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Anticoagulants market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Genentech (United States), Bristol-Myers Squibb (United States), The Medicines Company (United States), Boehringer Ingelheim (Germany), Otsuka (Japan), Bayer (Germany), Sanofi (France), AstraZeneca (United Kingdom), Lilly (United States), Johnson & Johnson (United States) and Bristol-Myers Squibb Company (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Portola Pharmaceuticals, Inc. (San Francisco), Pfizer, Inc. (United States) and Daiichi Sankyo Company, Limited (Japan).

Segmentation Overview
AMA Research has segmented the market of Global Anticoagulants market by Type (Vitamin K Antagonists, Non-VKA Oral Anticoagulants and Others), Application (Atrial Fibrillation & Heart Attack, Stroke, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE) and Others) and Region.



On the basis of geography, the market of Anticoagulants has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Route of Administration, the sub-segment i.e. Oral Anticoagulant will boost the Anticoagulants market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Drug Class , the sub-segment i.e. NOACs will boost the Anticoagulants market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increasing Demand for Oral Anticoagulants

Market Growth Drivers:
Increasing Number of cardiovascular diseases & blood disorders and Growing Geriatric Population

Challenges:
Immoral Amount Causes Excess Bleeding and Depletion of Vitamin D Increases Risk of Arterial Disorder

Restraints:
Stringent Government Regulation regarding Drugs Production and High-Cost Associated with Novel Oral Anticoagulants

Opportunities:
Rising Demand for Outpatient Management for Anticoagulation Treatment and Growing Healthcare Infrastructure Worldwide

Market Leaders and their expansionary development strategies
In September 2023, Bayer and Alnylam Pharmaceuticals announced a collaboration to develop and commercialize RNAi therapeutics for the treatment of thrombosis, a condition related to blood clots.
In August 2023, Novartis and Janssen Pharmaceuticals entered into a strategic partnership to develop and commercialize a new oral anticoagulant for the prevention of venous thromboembolism (VTE).


Key Target Audience
Healthcare service providers, Healthcare service payers/insurance payers, Pharmaceutical companies, Medical device companies, Government bodies, Business research and consulting firms, Research Institutes and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Vitamin K Antagonists
  • Non-VKA Oral Anticoagulants
  • Others
By Application
  • Atrial Fibrillation & Heart Attack
  • Stroke
  • Deep Vein Thrombosis (DVT)
  • Pulmonary Embolism (PE)
  • Others
By Route of Administration
  • Oral Anticoagulant
  • Injectable Anticoagulant

By Drug Class
  • NOACs
  • Heparin & LMWH
  • Vitamin K Antagonist
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Number of cardiovascular diseases & blood disorders
      • 3.2.2. Growing Geriatric Population
    • 3.3. Market Challenges
      • 3.3.1. Immoral Amount Causes Excess Bleeding
      • 3.3.2. Depletion of Vitamin D Increases Risk of Arterial Disorder
    • 3.4. Market Trends
      • 3.4.1. Increasing Demand for Oral Anticoagulants
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Anticoagulants, by Type, Application, Route of Administration, Drug Class and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Anticoagulants (Value)
      • 5.2.1. Global Anticoagulants by: Type (Value)
        • 5.2.1.1. Vitamin K Antagonists
        • 5.2.1.2. Non-VKA Oral Anticoagulants
        • 5.2.1.3. Others
      • 5.2.2. Global Anticoagulants by: Application (Value)
        • 5.2.2.1. Atrial Fibrillation & Heart Attack
        • 5.2.2.2. Stroke
        • 5.2.2.3. Deep Vein Thrombosis (DVT)
        • 5.2.2.4. Pulmonary Embolism (PE)
        • 5.2.2.5. Others
      • 5.2.3. Global Anticoagulants by: Route of Administration (Value)
        • 5.2.3.1. Oral Anticoagulant
        • 5.2.3.2. Injectable Anticoagulant
      • 5.2.4. Global Anticoagulants Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Anticoagulants (Price)
      • 5.3.1. Global Anticoagulants by: Type (Price)
  • 6. Anticoagulants: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Genentech (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bristol-Myers Squibb (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. The Medicines Company (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Boehringer Ingelheim (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Otsuka (Japan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Bayer (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Sanofi (France)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. AstraZeneca (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Lilly (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Johnson & Johnson (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Bristol-Myers Squibb Company (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Anticoagulants Sale, by Type, Application, Route of Administration, Drug Class and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Anticoagulants (Value)
      • 7.2.1. Global Anticoagulants by: Type (Value)
        • 7.2.1.1. Vitamin K Antagonists
        • 7.2.1.2. Non-VKA Oral Anticoagulants
        • 7.2.1.3. Others
      • 7.2.2. Global Anticoagulants by: Application (Value)
        • 7.2.2.1. Atrial Fibrillation & Heart Attack
        • 7.2.2.2. Stroke
        • 7.2.2.3. Deep Vein Thrombosis (DVT)
        • 7.2.2.4. Pulmonary Embolism (PE)
        • 7.2.2.5. Others
      • 7.2.3. Global Anticoagulants by: Route of Administration (Value)
        • 7.2.3.1. Oral Anticoagulant
        • 7.2.3.2. Injectable Anticoagulant
      • 7.2.4. Global Anticoagulants Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Anticoagulants (Price)
      • 7.3.1. Global Anticoagulants by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Anticoagulants: by Type(USD Million)
  • Table 2. Anticoagulants Vitamin K Antagonists , by Region USD Million (2018-2023)
  • Table 3. Anticoagulants Non-VKA Oral Anticoagulants , by Region USD Million (2018-2023)
  • Table 4. Anticoagulants Others , by Region USD Million (2018-2023)
  • Table 5. Anticoagulants: by Application(USD Million)
  • Table 6. Anticoagulants Atrial Fibrillation & Heart Attack , by Region USD Million (2018-2023)
  • Table 7. Anticoagulants Stroke , by Region USD Million (2018-2023)
  • Table 8. Anticoagulants Deep Vein Thrombosis (DVT) , by Region USD Million (2018-2023)
  • Table 9. Anticoagulants Pulmonary Embolism (PE) , by Region USD Million (2018-2023)
  • Table 10. Anticoagulants Others , by Region USD Million (2018-2023)
  • Table 11. Anticoagulants: by Route of Administration(USD Million)
  • Table 12. Anticoagulants Oral Anticoagulant , by Region USD Million (2018-2023)
  • Table 13. Anticoagulants Injectable Anticoagulant , by Region USD Million (2018-2023)
  • Table 14. South America Anticoagulants, by Country USD Million (2018-2023)
  • Table 15. South America Anticoagulants, by Type USD Million (2018-2023)
  • Table 16. South America Anticoagulants, by Application USD Million (2018-2023)
  • Table 17. South America Anticoagulants, by Route of Administration USD Million (2018-2023)
  • Table 18. South America Anticoagulants, by Drug Class USD Million (2018-2023)
  • Table 19. Brazil Anticoagulants, by Type USD Million (2018-2023)
  • Table 20. Brazil Anticoagulants, by Application USD Million (2018-2023)
  • Table 21. Brazil Anticoagulants, by Route of Administration USD Million (2018-2023)
  • Table 22. Brazil Anticoagulants, by Drug Class USD Million (2018-2023)
  • Table 23. Argentina Anticoagulants, by Type USD Million (2018-2023)
  • Table 24. Argentina Anticoagulants, by Application USD Million (2018-2023)
  • Table 25. Argentina Anticoagulants, by Route of Administration USD Million (2018-2023)
  • Table 26. Argentina Anticoagulants, by Drug Class USD Million (2018-2023)
  • Table 27. Rest of South America Anticoagulants, by Type USD Million (2018-2023)
  • Table 28. Rest of South America Anticoagulants, by Application USD Million (2018-2023)
  • Table 29. Rest of South America Anticoagulants, by Route of Administration USD Million (2018-2023)
  • Table 30. Rest of South America Anticoagulants, by Drug Class USD Million (2018-2023)
  • Table 31. Asia Pacific Anticoagulants, by Country USD Million (2018-2023)
  • Table 32. Asia Pacific Anticoagulants, by Type USD Million (2018-2023)
  • Table 33. Asia Pacific Anticoagulants, by Application USD Million (2018-2023)
  • Table 34. Asia Pacific Anticoagulants, by Route of Administration USD Million (2018-2023)
  • Table 35. Asia Pacific Anticoagulants, by Drug Class USD Million (2018-2023)
  • Table 36. China Anticoagulants, by Type USD Million (2018-2023)
  • Table 37. China Anticoagulants, by Application USD Million (2018-2023)
  • Table 38. China Anticoagulants, by Route of Administration USD Million (2018-2023)
  • Table 39. China Anticoagulants, by Drug Class USD Million (2018-2023)
  • Table 40. Japan Anticoagulants, by Type USD Million (2018-2023)
  • Table 41. Japan Anticoagulants, by Application USD Million (2018-2023)
  • Table 42. Japan Anticoagulants, by Route of Administration USD Million (2018-2023)
  • Table 43. Japan Anticoagulants, by Drug Class USD Million (2018-2023)
  • Table 44. India Anticoagulants, by Type USD Million (2018-2023)
  • Table 45. India Anticoagulants, by Application USD Million (2018-2023)
  • Table 46. India Anticoagulants, by Route of Administration USD Million (2018-2023)
  • Table 47. India Anticoagulants, by Drug Class USD Million (2018-2023)
  • Table 48. South Korea Anticoagulants, by Type USD Million (2018-2023)
  • Table 49. South Korea Anticoagulants, by Application USD Million (2018-2023)
  • Table 50. South Korea Anticoagulants, by Route of Administration USD Million (2018-2023)
  • Table 51. South Korea Anticoagulants, by Drug Class USD Million (2018-2023)
  • Table 52. Taiwan Anticoagulants, by Type USD Million (2018-2023)
  • Table 53. Taiwan Anticoagulants, by Application USD Million (2018-2023)
  • Table 54. Taiwan Anticoagulants, by Route of Administration USD Million (2018-2023)
  • Table 55. Taiwan Anticoagulants, by Drug Class USD Million (2018-2023)
  • Table 56. Australia Anticoagulants, by Type USD Million (2018-2023)
  • Table 57. Australia Anticoagulants, by Application USD Million (2018-2023)
  • Table 58. Australia Anticoagulants, by Route of Administration USD Million (2018-2023)
  • Table 59. Australia Anticoagulants, by Drug Class USD Million (2018-2023)
  • Table 60. Rest of Asia-Pacific Anticoagulants, by Type USD Million (2018-2023)
  • Table 61. Rest of Asia-Pacific Anticoagulants, by Application USD Million (2018-2023)
  • Table 62. Rest of Asia-Pacific Anticoagulants, by Route of Administration USD Million (2018-2023)
  • Table 63. Rest of Asia-Pacific Anticoagulants, by Drug Class USD Million (2018-2023)
  • Table 64. Europe Anticoagulants, by Country USD Million (2018-2023)
  • Table 65. Europe Anticoagulants, by Type USD Million (2018-2023)
  • Table 66. Europe Anticoagulants, by Application USD Million (2018-2023)
  • Table 67. Europe Anticoagulants, by Route of Administration USD Million (2018-2023)
  • Table 68. Europe Anticoagulants, by Drug Class USD Million (2018-2023)
  • Table 69. Germany Anticoagulants, by Type USD Million (2018-2023)
  • Table 70. Germany Anticoagulants, by Application USD Million (2018-2023)
  • Table 71. Germany Anticoagulants, by Route of Administration USD Million (2018-2023)
  • Table 72. Germany Anticoagulants, by Drug Class USD Million (2018-2023)
  • Table 73. France Anticoagulants, by Type USD Million (2018-2023)
  • Table 74. France Anticoagulants, by Application USD Million (2018-2023)
  • Table 75. France Anticoagulants, by Route of Administration USD Million (2018-2023)
  • Table 76. France Anticoagulants, by Drug Class USD Million (2018-2023)
  • Table 77. Italy Anticoagulants, by Type USD Million (2018-2023)
  • Table 78. Italy Anticoagulants, by Application USD Million (2018-2023)
  • Table 79. Italy Anticoagulants, by Route of Administration USD Million (2018-2023)
  • Table 80. Italy Anticoagulants, by Drug Class USD Million (2018-2023)
  • Table 81. United Kingdom Anticoagulants, by Type USD Million (2018-2023)
  • Table 82. United Kingdom Anticoagulants, by Application USD Million (2018-2023)
  • Table 83. United Kingdom Anticoagulants, by Route of Administration USD Million (2018-2023)
  • Table 84. United Kingdom Anticoagulants, by Drug Class USD Million (2018-2023)
  • Table 85. Netherlands Anticoagulants, by Type USD Million (2018-2023)
  • Table 86. Netherlands Anticoagulants, by Application USD Million (2018-2023)
  • Table 87. Netherlands Anticoagulants, by Route of Administration USD Million (2018-2023)
  • Table 88. Netherlands Anticoagulants, by Drug Class USD Million (2018-2023)
  • Table 89. Rest of Europe Anticoagulants, by Type USD Million (2018-2023)
  • Table 90. Rest of Europe Anticoagulants, by Application USD Million (2018-2023)
  • Table 91. Rest of Europe Anticoagulants, by Route of Administration USD Million (2018-2023)
  • Table 92. Rest of Europe Anticoagulants, by Drug Class USD Million (2018-2023)
  • Table 93. MEA Anticoagulants, by Country USD Million (2018-2023)
  • Table 94. MEA Anticoagulants, by Type USD Million (2018-2023)
  • Table 95. MEA Anticoagulants, by Application USD Million (2018-2023)
  • Table 96. MEA Anticoagulants, by Route of Administration USD Million (2018-2023)
  • Table 97. MEA Anticoagulants, by Drug Class USD Million (2018-2023)
  • Table 98. Middle East Anticoagulants, by Type USD Million (2018-2023)
  • Table 99. Middle East Anticoagulants, by Application USD Million (2018-2023)
  • Table 100. Middle East Anticoagulants, by Route of Administration USD Million (2018-2023)
  • Table 101. Middle East Anticoagulants, by Drug Class USD Million (2018-2023)
  • Table 102. Africa Anticoagulants, by Type USD Million (2018-2023)
  • Table 103. Africa Anticoagulants, by Application USD Million (2018-2023)
  • Table 104. Africa Anticoagulants, by Route of Administration USD Million (2018-2023)
  • Table 105. Africa Anticoagulants, by Drug Class USD Million (2018-2023)
  • Table 106. North America Anticoagulants, by Country USD Million (2018-2023)
  • Table 107. North America Anticoagulants, by Type USD Million (2018-2023)
  • Table 108. North America Anticoagulants, by Application USD Million (2018-2023)
  • Table 109. North America Anticoagulants, by Route of Administration USD Million (2018-2023)
  • Table 110. North America Anticoagulants, by Drug Class USD Million (2018-2023)
  • Table 111. United States Anticoagulants, by Type USD Million (2018-2023)
  • Table 112. United States Anticoagulants, by Application USD Million (2018-2023)
  • Table 113. United States Anticoagulants, by Route of Administration USD Million (2018-2023)
  • Table 114. United States Anticoagulants, by Drug Class USD Million (2018-2023)
  • Table 115. Canada Anticoagulants, by Type USD Million (2018-2023)
  • Table 116. Canada Anticoagulants, by Application USD Million (2018-2023)
  • Table 117. Canada Anticoagulants, by Route of Administration USD Million (2018-2023)
  • Table 118. Canada Anticoagulants, by Drug Class USD Million (2018-2023)
  • Table 119. Mexico Anticoagulants, by Type USD Million (2018-2023)
  • Table 120. Mexico Anticoagulants, by Application USD Million (2018-2023)
  • Table 121. Mexico Anticoagulants, by Route of Administration USD Million (2018-2023)
  • Table 122. Mexico Anticoagulants, by Drug Class USD Million (2018-2023)
  • Table 123. Anticoagulants: by Type(USD/Units)
  • Table 124. Company Basic Information, Sales Area and Its Competitors
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Anticoagulants: by Type(USD Million)
  • Table 136. Anticoagulants Vitamin K Antagonists , by Region USD Million (2025-2030)
  • Table 137. Anticoagulants Non-VKA Oral Anticoagulants , by Region USD Million (2025-2030)
  • Table 138. Anticoagulants Others , by Region USD Million (2025-2030)
  • Table 139. Anticoagulants: by Application(USD Million)
  • Table 140. Anticoagulants Atrial Fibrillation & Heart Attack , by Region USD Million (2025-2030)
  • Table 141. Anticoagulants Stroke , by Region USD Million (2025-2030)
  • Table 142. Anticoagulants Deep Vein Thrombosis (DVT) , by Region USD Million (2025-2030)
  • Table 143. Anticoagulants Pulmonary Embolism (PE) , by Region USD Million (2025-2030)
  • Table 144. Anticoagulants Others , by Region USD Million (2025-2030)
  • Table 145. Anticoagulants: by Route of Administration(USD Million)
  • Table 146. Anticoagulants Oral Anticoagulant , by Region USD Million (2025-2030)
  • Table 147. Anticoagulants Injectable Anticoagulant , by Region USD Million (2025-2030)
  • Table 148. South America Anticoagulants, by Country USD Million (2025-2030)
  • Table 149. South America Anticoagulants, by Type USD Million (2025-2030)
  • Table 150. South America Anticoagulants, by Application USD Million (2025-2030)
  • Table 151. South America Anticoagulants, by Route of Administration USD Million (2025-2030)
  • Table 152. South America Anticoagulants, by Drug Class USD Million (2025-2030)
  • Table 153. Brazil Anticoagulants, by Type USD Million (2025-2030)
  • Table 154. Brazil Anticoagulants, by Application USD Million (2025-2030)
  • Table 155. Brazil Anticoagulants, by Route of Administration USD Million (2025-2030)
  • Table 156. Brazil Anticoagulants, by Drug Class USD Million (2025-2030)
  • Table 157. Argentina Anticoagulants, by Type USD Million (2025-2030)
  • Table 158. Argentina Anticoagulants, by Application USD Million (2025-2030)
  • Table 159. Argentina Anticoagulants, by Route of Administration USD Million (2025-2030)
  • Table 160. Argentina Anticoagulants, by Drug Class USD Million (2025-2030)
  • Table 161. Rest of South America Anticoagulants, by Type USD Million (2025-2030)
  • Table 162. Rest of South America Anticoagulants, by Application USD Million (2025-2030)
  • Table 163. Rest of South America Anticoagulants, by Route of Administration USD Million (2025-2030)
  • Table 164. Rest of South America Anticoagulants, by Drug Class USD Million (2025-2030)
  • Table 165. Asia Pacific Anticoagulants, by Country USD Million (2025-2030)
  • Table 166. Asia Pacific Anticoagulants, by Type USD Million (2025-2030)
  • Table 167. Asia Pacific Anticoagulants, by Application USD Million (2025-2030)
  • Table 168. Asia Pacific Anticoagulants, by Route of Administration USD Million (2025-2030)
  • Table 169. Asia Pacific Anticoagulants, by Drug Class USD Million (2025-2030)
  • Table 170. China Anticoagulants, by Type USD Million (2025-2030)
  • Table 171. China Anticoagulants, by Application USD Million (2025-2030)
  • Table 172. China Anticoagulants, by Route of Administration USD Million (2025-2030)
  • Table 173. China Anticoagulants, by Drug Class USD Million (2025-2030)
  • Table 174. Japan Anticoagulants, by Type USD Million (2025-2030)
  • Table 175. Japan Anticoagulants, by Application USD Million (2025-2030)
  • Table 176. Japan Anticoagulants, by Route of Administration USD Million (2025-2030)
  • Table 177. Japan Anticoagulants, by Drug Class USD Million (2025-2030)
  • Table 178. India Anticoagulants, by Type USD Million (2025-2030)
  • Table 179. India Anticoagulants, by Application USD Million (2025-2030)
  • Table 180. India Anticoagulants, by Route of Administration USD Million (2025-2030)
  • Table 181. India Anticoagulants, by Drug Class USD Million (2025-2030)
  • Table 182. South Korea Anticoagulants, by Type USD Million (2025-2030)
  • Table 183. South Korea Anticoagulants, by Application USD Million (2025-2030)
  • Table 184. South Korea Anticoagulants, by Route of Administration USD Million (2025-2030)
  • Table 185. South Korea Anticoagulants, by Drug Class USD Million (2025-2030)
  • Table 186. Taiwan Anticoagulants, by Type USD Million (2025-2030)
  • Table 187. Taiwan Anticoagulants, by Application USD Million (2025-2030)
  • Table 188. Taiwan Anticoagulants, by Route of Administration USD Million (2025-2030)
  • Table 189. Taiwan Anticoagulants, by Drug Class USD Million (2025-2030)
  • Table 190. Australia Anticoagulants, by Type USD Million (2025-2030)
  • Table 191. Australia Anticoagulants, by Application USD Million (2025-2030)
  • Table 192. Australia Anticoagulants, by Route of Administration USD Million (2025-2030)
  • Table 193. Australia Anticoagulants, by Drug Class USD Million (2025-2030)
  • Table 194. Rest of Asia-Pacific Anticoagulants, by Type USD Million (2025-2030)
  • Table 195. Rest of Asia-Pacific Anticoagulants, by Application USD Million (2025-2030)
  • Table 196. Rest of Asia-Pacific Anticoagulants, by Route of Administration USD Million (2025-2030)
  • Table 197. Rest of Asia-Pacific Anticoagulants, by Drug Class USD Million (2025-2030)
  • Table 198. Europe Anticoagulants, by Country USD Million (2025-2030)
  • Table 199. Europe Anticoagulants, by Type USD Million (2025-2030)
  • Table 200. Europe Anticoagulants, by Application USD Million (2025-2030)
  • Table 201. Europe Anticoagulants, by Route of Administration USD Million (2025-2030)
  • Table 202. Europe Anticoagulants, by Drug Class USD Million (2025-2030)
  • Table 203. Germany Anticoagulants, by Type USD Million (2025-2030)
  • Table 204. Germany Anticoagulants, by Application USD Million (2025-2030)
  • Table 205. Germany Anticoagulants, by Route of Administration USD Million (2025-2030)
  • Table 206. Germany Anticoagulants, by Drug Class USD Million (2025-2030)
  • Table 207. France Anticoagulants, by Type USD Million (2025-2030)
  • Table 208. France Anticoagulants, by Application USD Million (2025-2030)
  • Table 209. France Anticoagulants, by Route of Administration USD Million (2025-2030)
  • Table 210. France Anticoagulants, by Drug Class USD Million (2025-2030)
  • Table 211. Italy Anticoagulants, by Type USD Million (2025-2030)
  • Table 212. Italy Anticoagulants, by Application USD Million (2025-2030)
  • Table 213. Italy Anticoagulants, by Route of Administration USD Million (2025-2030)
  • Table 214. Italy Anticoagulants, by Drug Class USD Million (2025-2030)
  • Table 215. United Kingdom Anticoagulants, by Type USD Million (2025-2030)
  • Table 216. United Kingdom Anticoagulants, by Application USD Million (2025-2030)
  • Table 217. United Kingdom Anticoagulants, by Route of Administration USD Million (2025-2030)
  • Table 218. United Kingdom Anticoagulants, by Drug Class USD Million (2025-2030)
  • Table 219. Netherlands Anticoagulants, by Type USD Million (2025-2030)
  • Table 220. Netherlands Anticoagulants, by Application USD Million (2025-2030)
  • Table 221. Netherlands Anticoagulants, by Route of Administration USD Million (2025-2030)
  • Table 222. Netherlands Anticoagulants, by Drug Class USD Million (2025-2030)
  • Table 223. Rest of Europe Anticoagulants, by Type USD Million (2025-2030)
  • Table 224. Rest of Europe Anticoagulants, by Application USD Million (2025-2030)
  • Table 225. Rest of Europe Anticoagulants, by Route of Administration USD Million (2025-2030)
  • Table 226. Rest of Europe Anticoagulants, by Drug Class USD Million (2025-2030)
  • Table 227. MEA Anticoagulants, by Country USD Million (2025-2030)
  • Table 228. MEA Anticoagulants, by Type USD Million (2025-2030)
  • Table 229. MEA Anticoagulants, by Application USD Million (2025-2030)
  • Table 230. MEA Anticoagulants, by Route of Administration USD Million (2025-2030)
  • Table 231. MEA Anticoagulants, by Drug Class USD Million (2025-2030)
  • Table 232. Middle East Anticoagulants, by Type USD Million (2025-2030)
  • Table 233. Middle East Anticoagulants, by Application USD Million (2025-2030)
  • Table 234. Middle East Anticoagulants, by Route of Administration USD Million (2025-2030)
  • Table 235. Middle East Anticoagulants, by Drug Class USD Million (2025-2030)
  • Table 236. Africa Anticoagulants, by Type USD Million (2025-2030)
  • Table 237. Africa Anticoagulants, by Application USD Million (2025-2030)
  • Table 238. Africa Anticoagulants, by Route of Administration USD Million (2025-2030)
  • Table 239. Africa Anticoagulants, by Drug Class USD Million (2025-2030)
  • Table 240. North America Anticoagulants, by Country USD Million (2025-2030)
  • Table 241. North America Anticoagulants, by Type USD Million (2025-2030)
  • Table 242. North America Anticoagulants, by Application USD Million (2025-2030)
  • Table 243. North America Anticoagulants, by Route of Administration USD Million (2025-2030)
  • Table 244. North America Anticoagulants, by Drug Class USD Million (2025-2030)
  • Table 245. United States Anticoagulants, by Type USD Million (2025-2030)
  • Table 246. United States Anticoagulants, by Application USD Million (2025-2030)
  • Table 247. United States Anticoagulants, by Route of Administration USD Million (2025-2030)
  • Table 248. United States Anticoagulants, by Drug Class USD Million (2025-2030)
  • Table 249. Canada Anticoagulants, by Type USD Million (2025-2030)
  • Table 250. Canada Anticoagulants, by Application USD Million (2025-2030)
  • Table 251. Canada Anticoagulants, by Route of Administration USD Million (2025-2030)
  • Table 252. Canada Anticoagulants, by Drug Class USD Million (2025-2030)
  • Table 253. Mexico Anticoagulants, by Type USD Million (2025-2030)
  • Table 254. Mexico Anticoagulants, by Application USD Million (2025-2030)
  • Table 255. Mexico Anticoagulants, by Route of Administration USD Million (2025-2030)
  • Table 256. Mexico Anticoagulants, by Drug Class USD Million (2025-2030)
  • Table 257. Anticoagulants: by Type(USD/Units)
  • Table 258. Research Programs/Design for This Report
  • Table 259. Key Data Information from Secondary Sources
  • Table 260. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Anticoagulants: by Type USD Million (2018-2023)
  • Figure 5. Global Anticoagulants: by Application USD Million (2018-2023)
  • Figure 6. Global Anticoagulants: by Route of Administration USD Million (2018-2023)
  • Figure 7. South America Anticoagulants Share (%), by Country
  • Figure 8. Asia Pacific Anticoagulants Share (%), by Country
  • Figure 9. Europe Anticoagulants Share (%), by Country
  • Figure 10. MEA Anticoagulants Share (%), by Country
  • Figure 11. North America Anticoagulants Share (%), by Country
  • Figure 12. Global Anticoagulants: by Type USD/Units (2018-2023)
  • Figure 13. Global Anticoagulants share by Players 2023 (%)
  • Figure 14. Global Anticoagulants share by Players (Top 3) 2023(%)
  • Figure 15. Global Anticoagulants share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Genentech (United States) Revenue, Net Income and Gross profit
  • Figure 18. Genentech (United States) Revenue: by Geography 2023
  • Figure 19. Bristol-Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 20. Bristol-Myers Squibb (United States) Revenue: by Geography 2023
  • Figure 21. The Medicines Company (United States) Revenue, Net Income and Gross profit
  • Figure 22. The Medicines Company (United States) Revenue: by Geography 2023
  • Figure 23. Boehringer Ingelheim (Germany) Revenue, Net Income and Gross profit
  • Figure 24. Boehringer Ingelheim (Germany) Revenue: by Geography 2023
  • Figure 25. Otsuka (Japan) Revenue, Net Income and Gross profit
  • Figure 26. Otsuka (Japan) Revenue: by Geography 2023
  • Figure 27. Bayer (Germany) Revenue, Net Income and Gross profit
  • Figure 28. Bayer (Germany) Revenue: by Geography 2023
  • Figure 29. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 30. Sanofi (France) Revenue: by Geography 2023
  • Figure 31. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 32. AstraZeneca (United Kingdom) Revenue: by Geography 2023
  • Figure 33. Lilly (United States) Revenue, Net Income and Gross profit
  • Figure 34. Lilly (United States) Revenue: by Geography 2023
  • Figure 35. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 36. Johnson & Johnson (United States) Revenue: by Geography 2023
  • Figure 37. Bristol-Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 38. Bristol-Myers Squibb Company (United States) Revenue: by Geography 2023
  • Figure 39. Global Anticoagulants: by Type USD Million (2025-2030)
  • Figure 40. Global Anticoagulants: by Application USD Million (2025-2030)
  • Figure 41. Global Anticoagulants: by Route of Administration USD Million (2025-2030)
  • Figure 42. South America Anticoagulants Share (%), by Country
  • Figure 43. Asia Pacific Anticoagulants Share (%), by Country
  • Figure 44. Europe Anticoagulants Share (%), by Country
  • Figure 45. MEA Anticoagulants Share (%), by Country
  • Figure 46. North America Anticoagulants Share (%), by Country
  • Figure 47. Global Anticoagulants: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Genentech (United States)
  • Bristol-Myers Squibb (United States)
  • The Medicines Company (United States)
  • Boehringer Ingelheim (Germany)
  • Otsuka (Japan)
  • Bayer (Germany)
  • Sanofi (France)
  • AstraZeneca (United Kingdom)
  • Lilly (United States)
  • Johnson & Johnson (United States)
  • Bristol-Myers Squibb Company (United States)
Additional players considered in the study are as follows:
Portola Pharmaceuticals, Inc. (San Francisco) , Pfizer, Inc. (United States) , Daiichi Sankyo Company, Limited (Japan)
Select User Access Type

Key Highlights of Report


Jan 2024 227 Pages 63 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Anticoagulants Market Quantitative research analysis
Global Anticoagulants Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Genentech (United States), Bristol-Myers Squibb (United States), The Medicines Company (United States), Boehringer Ingelheim (Germany), Otsuka (Japan), Bayer (Germany), Sanofi (France), AstraZeneca (United Kingdom), Lilly (United States), Johnson & Johnson (United States) and Bristol-Myers Squibb Company (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increasing Demand for Oral Anticoagulants" is seen as one of major influencing trends for Anticoagulants Market during projected period 2023-2030.
The Anticoagulants market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Anticoagulants Market Report?

Have a Query? Click Here

Other Related Reports

Valerian Oil Comprehensive Study by Type (Solution, Soft Gel Capsule, Others), Application (Pharmaceutical, Aromatherapy, Personal Care, Food & Beverages, Others), Sales Channels (Direct Sales, Indir...
$ 3650
HPV Vaccines Comprehensive Study by Type (Gardasils, Gardasil 9, Cervarix), Age Group (Adolescent, Adults), Disease Indication (Cervical Cancer, Cancer, Vaginal Cancer, Vulvar Cancer, Oropharyngeal C...
$ 3500
Arteriovenous Fistula Treatment Comprehensive Study by Type (Drugs, Transcatheter Embolization, Ultrasound-guided Compression, Surgery), Application (Diagnostic Centers, Hospitals, Clinics, Homecare,...
$ 3750
Brucellosis Vaccines Comprehensive Study by Type (DNA Vaccines, Subunit Vaccines, Vector Vaccines, B. Abortus Recombinant Mutants, Others), Application (Cattle, Sheep, Goats, Pigs, Others), Distribut...
$ 3750
Drugs for Vulvovaginal Candidiasis Comprehensive Study by Type (Miconazole, Clotrimazole, Fluconazole, Econazole, Other), Application (Clotrimazole,, Miconazole,, Terconazole,, Tioconazole,), Formula...
$ 3500
Achondroplasia Treatment Comprehensive Study by Type (RBM-007, TA-46, B-701, Others), Application (Hospital, Clinic, Others) Players and Region - Global Market Outlook to 2030
$ 3500